Emcure Pharmaceuticals Ltd
EMCUREEmcure Pharmaceuticals Ltd's earnings have outrun its stock. EPS grew +35.6% in a year against a +30.4% price move.
Biggest watch item: the P/E sits at the 73rd percentile of its own range — the multiple has already done part of the work.
The price is in a confirmed uptrend (54 weeks in) while the P/E sits at the 73rd percentile of its own 2-year range. Underneath, the last four quarters read improving — profit +23.9% year on year, and 133% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Emcure Pharmaceuticals Ltd trades at ₹1,783, in a confirmed uptrend and 54 weeks into that stage. That is +13.2% against its own 200-day average. It sits at 84% of a 52-week range of ₹1,284 to ₹1,880. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 9 straight weeks.
Today the stock is in a confirmed uptrend — week 54 of stage 2, confirmed. At ₹1,783 it trades +13.2% versus its 200-day average and sits at 84% of its 52-week range (₹1,284–₹1,880).
Against the market, two honest reads. Cumulative: over the last 2.0 years the stock moved +31% while the NIFTY 500 moved +1% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 9 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 73rd percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Emcure Pharmaceuticals Ltd trades at 37.7× P/E, at the pricey end of its own range (73rd percentile). Its long-run median P/E is 35.0×, measured across 2.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 37.7× is at the pricey end of its own range (73rd percentile), against a long-run median of 35.0× measured over 2.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +35.6% against a +30.4% price move — earnings outran the price, pushing the multiple DOWN its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 7.2% on reported income across 12 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Emcure Pharmaceuticals Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE lifting at 24.0% — the per-curve reads carry the story. The read is built from 8 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +16.6% | +15.4% | +12.8% | — |
| Profit | +33.1% | +18.7% | +17.6% | — |
| EPS | +35.6% | +18.3% | +16.1% | — |
| Share price | +30.4% | — | — | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
60.0/100 — rank 8 of 43 in Pharma - Formulators · 72% evidence confidence
Emcure Pharmaceuticals Ltd scores 60.0 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 8. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 25 + 16.9 + 9.7 + 8.4 = 60. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Emcure Pharmaceuticals Ltd reported ₹2,470 Cr of revenue in the Mar 26 quarter, +16.7% year on year. That is the 8th straight quarter of year-on-year growth. Over 7 years it has compounded at 10.0% a year. The last full year, FY26, came in at ₹9,204 Cr. The last four reported quarters add to ₹9,204 Cr.
Emcure Pharmaceuticals Ltd reported ₹2,470 Cr of revenue in the Mar 26 quarter, +16.7% year on year. That is the 8th straight quarter of year-on-year growth. Over 7 years it has compounded at 10.0% a year. The last full year, FY26, came in at ₹9,204 Cr. The last four reported quarters add to ₹9,204 Cr.
FY26 revenue came in at ₹9,204 Cr (+16.6% on the year), capping 7 years at 10.0% compound. The latest quarter (Mar 26) printed ₹2,470 Cr, +16.7% year on year — the 8th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +16.6% growth against the decade's 10.0% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +16.6% over the last 4 quarters against +17.6%/yr over the last 8 — stabilising; TTM profit +32.9% vs +33.5%/yr — stabilising.
→ Revenue grew — did margins hold as it scaled? Next: 19.0% this quarter (+0.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Emcure Pharmaceuticals Ltd's operating margin is 19.0% in the Mar 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 14.0% to 24.0%. The current quarter sits inside that band.
Emcure Pharmaceuticals Ltd's operating margin is 19.0% in the Mar 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 14.0% to 24.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 19.0%, +0.0 pp against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 14.0%–24.0%.
Why the margin moved: operating margin went +0.4 pp year on year while gross margin went −0.2 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
→ Margins held — did that reach the bottom line? Next: profit +23.9% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Emcure Pharmaceuticals Ltd earned ₹244 Cr of net profit in the Mar 26 quarter, +23.9% year on year. It is the 8th consecutive quarter of growth. Full-year FY26 profit was ₹941 Cr. The 7-year compound rate is 24.0%. That is 9.9% of the quarter's revenue. The same quarter a year earlier earned ₹197 Cr.
Emcure Pharmaceuticals Ltd earned ₹244 Cr of net profit in the Mar 26 quarter, +23.9% year on year. It is the 8th consecutive quarter of growth. Full-year FY26 profit was ₹941 Cr. The 7-year compound rate is 24.0%. That is 9.9% of the quarter's revenue. The same quarter a year earlier earned ₹197 Cr.
Mar 26 profit was ₹244 Cr, +23.9% year on year — the 8th consecutive quarter of growth. On the full year, FY26 printed ₹941 Cr (+33.1%), and the 7-year compound rate is 24.0%.
Why profit moved: revenue contributed +16.7% and the margin +0.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +34.2% vs revenue +16.6%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
→ Profit rose — but did the cash follow? Next: 133% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 133% of Emcure Pharmaceuticals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹944 Cr of operating cash against ₹941 Cr of profit. After ₹633 Cr of capital spending, ₹311 Cr was left as free cash.
FY26: operating cash of ₹944 Cr against reported profit of ₹941 Cr, leaving free cash of ₹311 Cr after ₹633 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 133% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 133%: the cash cycle tightened 49 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 1.9× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹2,145 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Emcure Pharmaceuticals Ltd's cash conversion cycle runs 163 days in FY26, down from 212 days in FY21. Capital spending ran ₹2,145 Cr over the last 3 years. At FY26 sales of ₹9,204 Cr each day of that cycle holds about ₹25.2 Cr, so roughly ₹4,110 Cr sits inside the business at any moment.
FY26: debtors at 102 days, inventory at 237 days — roughly 7.8 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 163 days, tighter than FY21's 212.
The full loop: cash goes out to suppliers and production on day 0; stock waits 237 days to sell; customers pay about 102 days after that; and suppliers themselves are paid at 175 days — netting out to the 163-day cycle.
In money terms: at FY26 sales of ₹9,204 Cr, each day of the cycle holds about ₹25.2 Cr — so the 163-day loop keeps roughly ₹4,110 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹2,145 Cr over the last 3 fiscal years against ₹1,111 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹172 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 24%.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Emcure Pharmaceuticals Ltd earns a ROCE of 24% in FY26. That is up from a trough of 11% in FY20. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 10.2% net margin on 0.96× asset turns.
FY26 ROCE is 24%, recovered from a FY20 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 10.2% net margin × 0.96× asset turns × 1.94× balance-sheet leverage ≈ 19.0% on equity. Margin does its share; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 7.2% on reported income across 12 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.31.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Emcure Pharmaceuticals Ltd carries ₹1,558 Cr of borrowings against ₹4,950 Cr of equity in FY26, a debt-to-equity of 0.31. Operating profit covers the interest bill 13×. Over 5 years borrowings went from ₹2,310 Cr to ₹1,558 Cr. Capital spending ran ₹2,145 Cr across the last 3 of those years.
FY26: borrowings of ₹1,558 Cr against equity of ₹4,950 Cr — a debt-to-equity of 0.31. Operating profit covers the interest bill 13×. Over 5 years borrowings went from ₹2,310 Cr to ₹1,558 Cr while capital spending ran ₹2,145 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 7.2% on reported income across 12 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Who owns this, and are they adding or leaving? Next: Domestic institutions added 4.5 points over 7 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 4.5 points of Emcure Pharmaceuticals Ltd over 7 quarters, the biggest move on the register. That takes domestic institutions to 8.5% of the company. Foreign institutions moved +2.0 points over the same window, to 4.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +4.5 points over 7 quarters to 8.5%; Foreign institutions: +2.0 points over 7 quarters to 4.9%; Promoters: −0.3 points over 7 quarters to 77.8%.
Why the register moved: domestic institutions drove it (+4.5 points), alongside foreign institutions (+2.0 points) — steady accumulation by institutions reading the same numbers this page reads.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Emcure Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals Ltd this page | 37.7× | ₹35,679 Cr | Mixed | |||
| Sun Pharmaceutical Industries Ltd | 37.5× | ₹4.7L Cr | Improving | |||
| Torrent Pharmaceuticals Ltd | 86.1× | ₹1.9L Cr | Consistent | |||
| Cipla Ltd | 31.8× | ₹1.1L Cr | Deteriorating | |||
| Zydus Lifesciences Ltd | 20.4× | ₹1.1L Cr | Consistent | |||
| Lupin Ltd | 19.1× | ₹1.1L Cr | Consistent | |||
| Mankind Pharma Ltd | 51.4× | ₹1L Cr | Turning around | |||
| Dr Reddys Laboratories Ltd | 29.8× | ₹96,130 Cr | Deteriorating | |||
| Aurobindo Pharma Ltd | 25.1× | ₹88,979 Cr | Mixed | |||
| Biocon Ltd | 182.0× | ₹70,672 Cr | Deteriorating | |||
| Alkem Laboratories Ltd | 27.6× | ₹67,357 Cr | Mixed | |||
| Glenmark Pharmaceuticals Ltd | 21.0× | ₹61,858 Cr | No read | |||
| Ipca Laboratories Ltd | 37.9× | ₹44,720 Cr | Consistent | |||
| Ajanta Pharma Ltd | 37.3× | ₹42,097 Cr | Consistent | |||
| J B Chemicals & Pharmaceuticals Ltd | 53.8× | ₹38,677 Cr | Topping out | |||
| Wockhardt Ltd | 106.0× | ₹30,048 Cr | No read | |||
| Rubicon Research Ltd | 102.0× | ₹25,141 Cr | No read | |||
| ERIS Lifesciences Ltd | 30.7× | ₹19,409 Cr | Turning around | |||
| Caplin Point Laboratories Ltd | 29.2× | ₹18,753 Cr | Consistent | |||
| Natco Pharma Ltd | 11.6× | ₹16,504 Cr | Topping out | |||
| Alembic Pharmaceuticals Ltd | 21.4× | ₹15,678 Cr | Turning around | |||
| Corona Remedies Ltd | 64.7× | ₹12,923 Cr | No read | |||
| Marksans Pharma Ltd | 26.7× | ₹11,161 Cr | Consistent | |||
| Akums Drugs & Pharmaceuticals Ltd | 40.3× | ₹10,818 Cr | No read | |||
| Strides Pharma Science Ltd | 16.6× | ₹9,402 Cr | No read | |||
| Suven Life Sciences Ltd | — | ₹8,929 Cr | No read | |||
| FDC Ltd | 22.6× | ₹6,723 Cr | Turning around | |||
| Bliss GVS Pharma Ltd | 37.4× | ₹4,927 Cr | Turning around | |||
| RPG Life Sciences Ltd | 44.3× | ₹4,858 Cr | — | — | — | — |
| Gufic BioSciences Ltd | 59.2× | ₹3,799 Cr | No read | |||
| Kwality Pharmaceuticals Ltd | 42.5× | ₹2,886 Cr | Consistent | |||
| Kwality Pharmaceuticals Ltd | 36.6× | ₹2,483 Cr | Consistent | |||
| Sai Parenterals Ltd | 166.0× | ₹2,366 Cr | — | — | — | — |
| Indoco Remedies Ltd | — | ₹2,247 Cr | No read | |||
| Fredun Pharmaceuticals Ltd | 45.4× | ₹1,480 Cr | — | No read | ||
| Amrutanjan Health Care Ltd | 22.8× | ₹1,472 Cr | Mixed | |||
| Accent Microcell Ltd | 27.1× | ₹1,187 Cr | No read | |||
| Lincoln Pharmaceuticals Ltd | 13.2× | ₹1,162 Cr | Turning around | |||
| Bajaj Healthcare Ltd | 19.3× | ₹1,088 Cr | No read | |||
| Bharat Parenterals Ltd | — | ₹990 Cr | No read |
Frequently asked questions
What is Emcure Pharmaceuticals Ltd's share price today?
Emcure Pharmaceuticals Ltd trades at ₹1,783, +30.4% over the past year. The company is valued at ₹35,679 Cr. The stock sits at 84% of its 52-week range of ₹1,284–₹1,880, +13.2% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 54 weeks in. — as of 24 July 2026.
What were Emcure Pharmaceuticals Ltd's latest quarterly results?
Emcure Pharmaceuticals Ltd reported revenue of ₹2,470 Cr and net profit of ₹244 Cr for the Mar 26 quarter. Revenue rose 16.7% and profit rose 23.9% year on year. Earnings per share were ₹12.84. The operating margin was 19.0%, 0.0 pp higher than a year earlier. — as of 24 July 2026.
What is Emcure Pharmaceuticals Ltd's revenue?
Emcure Pharmaceuticals Ltd reported revenue of ₹2,470 Cr in the Mar 26 quarter, +16.7% year on year. For the full FY26 fiscal year, revenue was ₹9,204 Cr (+16.6%). Over the last 7 years revenue compounded at 10.0% a year. — as of 24 July 2026.
What is Emcure Pharmaceuticals Ltd's profit?
Emcure Pharmaceuticals Ltd earned ₹244 Cr of net profit in the Mar 26 quarter, +23.9% year on year — the 8th straight quarter of growth. Full-year FY26 profit was ₹941 Cr. The operating margin ran 19.0% in the latest quarter. — as of 24 July 2026.
What is Emcure Pharmaceuticals Ltd's market cap?
Emcure Pharmaceuticals Ltd's market capitalisation is ₹35,679 Cr at a share price of ₹1,783. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Emcure Pharmaceuticals Ltd's P/E ratio?
Emcure Pharmaceuticals Ltd trades at a P/E of 37.7×, at the 73rd percentile of its own 2-year range, against a long-run median of 35.0×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Emcure Pharmaceuticals Ltd pay a dividend?
Yes — Emcure Pharmaceuticals Ltd's dividend payout was 7% of profit in FY26, and it recorded a payout in each of its last 8 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Emcure Pharmaceuticals Ltd overvalued?
On its own history, Emcure Pharmaceuticals Ltd looks expensive against its own history: its P/E of 37.7× sits at the 73rd percentile of its 2-year range (long-run median 35.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Emcure Pharmaceuticals Ltd growing?
Yes — Emcure Pharmaceuticals Ltd is growing: latest-quarter revenue +16.7% year on year, profit +23.9%, and the margin +0.0 pp at 19.0%. The 7-year compound rates are 10.0% (revenue) and 24.0% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Emcure Pharmaceuticals Ltd performing?
Emcure Pharmaceuticals Ltd is in a confirmed uptrend, 54 weeks in. Its latest quarter's revenue rose 16.7% and profit rose 23.9% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Emcure Pharmaceuticals Ltd in?
Mixed — no clean majority across the growth curves, ROCE lifting at 24.0% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +16.7% latest, profit growth +23.9% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Emcure Pharmaceuticals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 54 of stage 2), trading +13.2% versus its 200-day average and at 84% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Emcure Pharmaceuticals Ltd beating the market?
On recent form, yes — Emcure Pharmaceuticals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 9 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 2.0 years the stock moved +31% against the NIFTY 500's +1% — ahead of the index over the full window. — as of 24 July 2026.
Will Emcure Pharmaceuticals Ltd's share price go up?
This page publishes no price forecast for Emcure Pharmaceuticals Ltd. What it measures instead: the share price is ₹1,783, the price is in a confirmed uptrend 54 weeks in. Its P/E of 37.7× sits at the 73rd percentile of its own 2-year range. — as of 24 July 2026.
Who owns Emcure Pharmaceuticals Ltd?
Promoters hold 77.8% of Emcure Pharmaceuticals Ltd, foreign institutions 4.9%, domestic institutions 8.5% and the public 8.8% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 4.5 points over 7 quarters. — as of 24 July 2026.
Does Emcure Pharmaceuticals Ltd have too much debt?
It is moderate — Emcure Pharmaceuticals Ltd's debt-to-equity is 0.31, and operating profit covers the interest bill 13×. FY26 borrowings were ₹1,558 Cr against equity of ₹4,950 Cr. Read the returns on this page with that leverage in mind — as of 24 July 2026.
What is Emcure Pharmaceuticals Ltd's capex?
Emcure Pharmaceuticals Ltd spent ₹2,145 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹633 Cr, with ₹172 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Emcure Pharmaceuticals Ltd's cash flow?
Emcure Pharmaceuticals Ltd generated ₹944 Cr of operating cash flow in FY26 and ₹311 Cr of free cash flow after ₹633 Cr of capital spending. Reported profit that year was ₹941 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Emcure Pharmaceuticals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 133% of Emcure Pharmaceuticals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹944 Cr against reported profit of ₹941 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is Emcure Pharmaceuticals Ltd in its business cycle?
Emcure Pharmaceuticals Ltd's FY26 operating margin was 20.0%, against a 8-year band of 14.0%–24.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 19.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Emcure Pharmaceuticals Ltd story?
Biggest watch item: the P/E sits at the 73rd percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Emcure Pharmaceuticals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Emcure Pharmaceuticals Ltd's earnings have outrun its stock. EPS grew +35.6% in a year against a +30.4% price move. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.